References
- 1. D. S. Dizon, L. Krilov, E. Cohen, T. Gangadhar, P. A. Ganz, T. A. Hensing, S. Hunger, S. S. Krishnamurthi, A. B. Lassman, M. J. Markham, E. Mayer, M. Neuss, S. K. Pal, L. C. Richardson, R. Schilsky, G. K. Schwartz, D. R. M. A. Spriggs, Villalona-Calero, G. Villani and G. Masters, Clinical cancer advances 2016: Annual report on progress against cancer from the American Society of Clinical Oncology, J. Clin. Oncol. 34 (2016) 987–1011; https://doi.org/10.1200/JCO.2015.65.8427
- 2. N. Holder and R. Klein, Eph receptors and ephrins: effectors of morphogenesis, Development10 (1999) 2033–2044.
- 3. J. E. Chrencik, A. Brooun, M. L. Kraus, M. I. Recht, A. R. Kolatkar, G. W. Han, J. M. Seifert, H. Widmer, M. Auer and P. Kuhn, Structural and biophysical characterization of the EphB4*ephrinB2 protein-protein interaction and receptor specificity, J. Biol. Chem. 38 (2006) 28185–28192; https://doi.org/10.1074/jbc.M605766200
- 4. S. S. Gerety, H. U. Wang, Z. F. Chen and D. J. Anderson, Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development, Mol. Cell. 3 (1999) 403–414.
- 5. J. Folkman, Angiogenesis in cancer, vascular, rheumatoid and other diseases, Nat. Med. 1 (1995) 27–31; https://doi.org/10.1038/nm0195-27
- 6. S. R. Kumar, J. Singh, G. Xia, V. Krasnoperov, L. Hassanieh, E. J. Ley, J. Scehnet, N. G. Kumar, D. Hawes, M. F. Press, F. A. Weaver and P. S. Gill, Receptor tyrosine kinase EphB4 is a survival factor in breast cancer, Am. J. Pathol. 169 (2006) 279–293; https://doi.org/10.2353/ajpath.2006.050889
- 7. D. Yang, C. Jin, H. Ma, M. Huang, G. Shi, J. Wang and M. Xiang, EphrinB2/EphB4 pathway in postnatal angiogenesis: a potential therapeutic target for ischemic cardiovascular disease, Angiogenesis19 (2016) 297–309; https://doi.org/10.1007/s10456-016-9514-9
- 8. C. Wang, J. Dong, Y. Zhang, F. Wang, H. Gao, P. Li, S. Wang and J. Zhang, Design, synthesis and biological evaluation of biphenyl urea derivatives as novel VEGFR-2 inhibitors, Medchemcomm11 (2013) 1434–1438; https://doi.org/10.1039/C3MD00192J
- 9. Q. Y. Chen, Y. Zheng, D. M. Jiao, F. Y. Chen, H. Z. Hu, Y. Q. Wu, J. Song, J. Yan, L. J. Wu and G. Y. Lv, Curcumin inhibits lung cancer cell migration and invasion through Rac1-dependent signaling pathway, J. Nutr. Biochem. 25 (2014) 177–185; https://doi.org/10.1016/j.jnutbio.2013.10.004
- 10. Y. Chen, G. Stamatoyannopoulos and C. Z. Song, Down-regulation of CXCR4 by inducible small interfering RNA inhibits breast cancer cell invasion in vitro, Cancer Res. 63 (2003) 4801–4804.
- 11. M. E. Pitulescu and R. H. Adams, Eph/ephrin molecules – a hub for signaling and endocytosis, Genes Dev. 24 (2010) 2480–2492; https://doi.org/10.1101/gad.1973910
- 12. J. S. Nielsen and K. M. McNagny, Novel functions of the CD34 family, J. Cell Sci. 121 (2008) 3683–3692; https://doi.org/10.1242/jcs.037507
- 13. T. Makinen, R. H. Adams, J. Bailey, Q. Lu, A. Ziemiecki, K. Alitalo, R. Klein and G. A. Wilkinson, PDZ interaction site in ephrinB2 is required for the remodeling of lymphatic vasculature, Genes Dev. 19 (2005) 397–410; https://doi.org/10.1101/gad.330105
- 14. T. V. Byzova, C. K. Goldman, N. Pampori, K. A. Thomas, A. Bett, S. J. Shattil and E. F. Plow, A mechanism for modulation of cellular responses to VEGF: activation of the integrins, Mol. Cell. 6 (2000) 851–860.
- 15. T. Makinen, T. Veikkola, S. Mustjoki, T. Karpanen, B. Catimel, E. C. Nice, L. Wise, A. Mercer, H. Kowalski, D. Kerjaschki, S. A. Stacker, M. G. Achen and K. Alitalo, Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3, EMBO J. 20 (2001) 4762–4773; https://doi.org/10.1093/emboj/20.17.4762